Tech Company Financing Transactions

OVATION Pharmaceuticals Funding Round

OVATION Pharmaceuticals secured a $37 million Series B venture capital round on 12/6/2004. Investors included FirstMark Capital, Accomplice and CNF Investments.

Transaction Overview

Company Name
OVATION Pharmaceuticals
Announced On
12/6/2004
Transaction Type
Venture Equity
Amount
$37,000,000
Round
Series B
Investors

FirstMark Capital (Lead Investor) (Patrick Enright)

Accomplice

CNF Investments

Scale Venture Partners

Sofinnova Ventures (James Healy)

Vivo Capital (Edgar Engleman)

Proceeds Purpose
The funds will be used to develop and commercialize its pipeline of products for central nervous system (CNS) disorders.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
Four Parkway North 200
Deerfield, IL 60015
USA
Phone
(800) 455-1141
Website
www.ovationpharma.com
Email Address
[email protected]
Overview
Prestwick Pharmaceuticals, Inc. is a product-based specialty pharmaceutical company engaged in the development and marketing of small molecule drugs for chronic diseases of the central nervous system.
Profile
OVATION Pharmaceuticals LinkedIn Company Profile
Social Media
OVATION Pharmaceuticals Company Twitter Account
Company News
OVATION Pharmaceuticals News
Facebook
OVATION Pharmaceuticals on Facebook
YouTube
OVATION Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jeffrey Aronin
  Jeffrey Aronin LinkedIn Profile  Jeffrey Aronin Twitter Account  Jeffrey Aronin News  Jeffrey Aronin on Facebook
Chief Financial Officer
Curtis Rhine
  Curtis Rhine LinkedIn Profile  Curtis Rhine Twitter Account  Curtis Rhine News  Curtis Rhine on Facebook
Vice President
Tim Cunniff
  Tim Cunniff LinkedIn Profile  Tim Cunniff Twitter Account  Tim Cunniff News  Tim Cunniff on Facebook
Vice President
Robert Holt
  Robert Holt LinkedIn Profile  Robert Holt Twitter Account  Robert Holt News  Robert Holt on Facebook
Vice President
Christopher Silber
  Christopher Silber LinkedIn Profile  Christopher Silber Twitter Account  Christopher Silber News  Christopher Silber on Facebook
Vice President
Bryan Stuart
  Bryan Stuart LinkedIn Profile  Bryan Stuart Twitter Account  Bryan Stuart News  Bryan Stuart on Facebook
Vice President
Samuel Yonren
  Samuel Yonren LinkedIn Profile  Samuel Yonren Twitter Account  Samuel Yonren News  Samuel Yonren on Facebook
Vice President
Sally Young
  Sally Young LinkedIn Profile  Sally Young Twitter Account  Sally Young News  Sally Young on Facebook
VP - General Counsel
Patrick Morris
  Patrick Morris LinkedIn Profile  Patrick Morris Twitter Account  Patrick Morris News  Patrick Morris on Facebook
VP - Human Resources
Lance Williams
  Lance Williams LinkedIn Profile  Lance Williams Twitter Account  Lance Williams News  Lance Williams on Facebook
VP - Operations
Marc Wipperman
  Marc Wipperman LinkedIn Profile  Marc Wipperman Twitter Account  Marc Wipperman News  Marc Wipperman on Facebook
VP - Product Management
Sean Nolan
  Sean Nolan LinkedIn Profile  Sean Nolan Twitter Account  Sean Nolan News  Sean Nolan on Facebook

 

 

Browse more venture capital transactions:

Prev: 12/4/2004: Catalyst Biosciences venture capital transaction
Next: 12/6/2004: Endocyte venture capital transaction

 

Share this article

 

About Database of VC Transactions

We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.